http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 New York and Petach Tikvah, Israel - November 11, 2009 - BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce... http://pharmalicensing.com/redirs/news_rss//public/news/view/499771/0/10/brainstorm-chief-medical-advisor-interviewed-on-israel-radio-broadcast-states-stem-cell-therapy-treatment-ready-for-clinical-trials http://pharmalicensing.com/redirs/news_rss//public/news/view/499771/0/10/brainstorm-chief-medical-advisor-interviewed-on-israel-radio-broadcast-states-stem-cell-therapy-treatment-ready-for-clinical-trials MENLO PARK, Calif., November 11, 2009 - Geron Corporation (Nasdaq: GERN) today announced the publication of data showing that oligodendrocyte progenitor cells (OPCs) derived from human embryonic stem... http://pharmalicensing.com/redirs/news_rss//public/news/view/499783/0/10/geron-collaborators-publish-data-on-hesc-derived-glial-progenitor-cell-therapy-in-cervical-spinal-cord-injury http://pharmalicensing.com/redirs/news_rss//public/news/view/499783/0/10/geron-collaborators-publish-data-on-hesc-derived-glial-progenitor-cell-therapy-in-cervical-spinal-cord-injury MENLO PARK, Calif.--November 10, 2009--SRI International, an independent nonprofit research and development organization, announced today that its Center for Neuroscience has entered into a research... http://pharmalicensing.com/redirs/news_rss//public/news/view/499647/0/10/sri-international-and-f-hoffmann-la-roche-launch-translational-medicine-collaboration-to-study-methods-and-treatments-associated-with-cognitive-deficits-across-neuropsychiatric-disorders http://pharmalicensing.com/redirs/news_rss//public/news/view/499647/0/10/sri-international-and-f-hoffmann-la-roche-launch-translational-medicine-collaboration-to-study-methods-and-treatments-associated-with-cognitive-deficits-across-neuropsychiatric-disorders November 10, 2009--Diamyd Inc, Pittsburgh, PA, USA, a wholly-owned subsidiary of Diamyd Medical, Stockholm Sweden, announces today that the United States Department of Veterans Affairs (VA) has... http://pharmalicensing.com/redirs/news_rss//public/news/view/499740/0/10/diamyd-technology-advances-with-us-1-84-million-grant http://pharmalicensing.com/redirs/news_rss//public/news/view/499740/0/10/diamyd-technology-advances-with-us-1-84-million-grant SOUTH SAN FRANCISCO, Calif. -November 10, 2009 - Cerimon Pharmaceuticals, Inc., announced today that it has acquired exclusive rights to develop and commercialize its once-daily topical diclofenac... http://pharmalicensing.com/redirs/news_rss//public/news/view/499606/0/10/cerimon-pharmaceuticals-acquires-european-rights-to-topical-diclofenac-patch-cerimon-also-completes-enrollment-of-phase-3-diclofenac-patch-studies-in-acute-pain-company-also-receives-notice-of-allowance-for-key-us-patent-application http://pharmalicensing.com/redirs/news_rss//public/news/view/499606/0/10/cerimon-pharmaceuticals-acquires-european-rights-to-topical-diclofenac-patch-cerimon-also-completes-enrollment-of-phase-3-diclofenac-patch-studies-in-acute-pain-company-also-receives-notice-of-allowance-for-key-us-patent-application CARLSBAD, Calif.-- November 10, 2009-- The University of Cambridge and Life Technologies Corporation (NASDAQ:LIFE), announced today the formation of a collaboration to advance translational research... http://pharmalicensing.com/redirs/news_rss//public/news/view/499618/0/10/university-of-cambridge-and-life-technologies-collaborate-on-landmark-high-throughput-sequencing-hub-in-united-kingdom http://pharmalicensing.com/redirs/news_rss//public/news/view/499618/0/10/university-of-cambridge-and-life-technologies-collaborate-on-landmark-high-throughput-sequencing-hub-in-united-kingdom THE WOODLANDS, Texas--November 04, 2009---Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the... http://pharmalicensing.com/redirs/news_rss//public/news/view/498887/0/10/opexa-therapeutics-reports-third-quarter-2009-financial-results-and-corporate-update http://pharmalicensing.com/redirs/news_rss//public/news/view/498887/0/10/opexa-therapeutics-reports-third-quarter-2009-financial-results-and-corporate-update NOVATO, Calif., Nov. 4, 2009 -- Raptor Pharmaceutical Corp. (Nasdaq: RPTP), today announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate... http://pharmalicensing.com/redirs/news_rss//public/news/view/498805/0/10/raptor-pharmaceutical-corporation-announces-presentation-of-data-for-ngx426-a-novel-non-opioid-oral-analgesic-at-neuropathic-pain-conference http://pharmalicensing.com/redirs/news_rss//public/news/view/498805/0/10/raptor-pharmaceutical-corporation-announces-presentation-of-data-for-ngx426-a-novel-non-opioid-oral-analgesic-at-neuropathic-pain-conference IRVINE, CA, Nov 03, 2009 -- BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser company, today announced the launch of the Diolase 10(TM) Diode Laser for therapeutic... http://pharmalicensing.com/redirs/news_rss//public/news/view/498529/0/10/biolase-introduces-the-diolase-10-tm-diode-laser-for-pain-management-therapeutic-applications http://pharmalicensing.com/redirs/news_rss//public/news/view/498529/0/10/biolase-introduces-the-diolase-10-tm-diode-laser-for-pain-management-therapeutic-applications Monday 02 November 2009, London UK and California US -- GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International (VRX) announced today that, on 30 October, they filed a New Drug Application... http://pharmalicensing.com/redirs/news_rss//public/news/view/498590/0/10/retigabine-regulatory-update http://pharmalicensing.com/redirs/news_rss//public/news/view/498590/0/10/retigabine-regulatory-update